Sun Targets US Long-Term Care And Eye Care
Launches Duloxetine Sprinkle Formulation And Cyclosporine Ophthalmic Solution
Sun Pharma has expanded its added-value medicines range for US long-term care residents by launching Drizalma Sprinkle duloxetine delayed-release capsules while it has also introduced novel Cequa cyclosporine eye drops.
You may also be interested in...
Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.
Xelpros may not be seen as a huge money-spinner, but its approval by the US FDA signals Sun Pharma's expanding interest in the US ophthalmology space. The clearance also potentially indicates that recent compliance issues at the company’s Halol site may not be all-encompassing.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.